Compared to aldesleukin, THOR-707 showed a specifically reduced potency for stimulation of suppressive Treg cells, demonstrating that the pharmacology of THOR-707 is reprogrammed toward stimulation of effector populations required for a potent anti-tumor response. The gene discussed is THORLNC; the disease is neoplasm.